Covid‐19 and dengue: Double punches for dengue‐endemic countries in Asia. (18th September 2020)

• Record Type: Journal Article
• Authors: Harapan, Harapan; Ryan, Mirza; Yohan, Benediktus; Abidin, Rufika Shari; Nainu, Firzan; Rakib, Ahmed; Jahan, Israt; Emran, Talha Bin; Ullah, Irfan; Panta, Kritu; Dhama, Kuldeep; Sasmono, R. Tedjo
• Is Part Of: Reviews in medical virology. Volume 31:Number 2(2021)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2020-09-18
• Subjects: ADE -- Covid‐19 -- cross‐reactivity -- dengue -- SARS‐CoV‐2; Medical virology -- Periodicals; Review Literature -- Periodicals; Virus Diseases -- Periodicals; Viruses -- Periodicals; 616.0194
• DOI: 10.1002/rmv.2161
• Languages: English
• ISSNs: 1052-9276

Abstract

Summary: The coronavirus disease 2019 (Covid‐19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), is an international public health crisis with devastating effects. In particular, this pandemic has further exacerbated the burden in tropical and subtropical regions of the world, where dengue fever, caused by dengue virus (DENV), is already endemic to the population. The similar clinical manifestations shared by Covid‐19 and dengue fever have raised concerns, especially in dengue‐endemic countries with limited resources, leading to diagnostic challenges. In addition, cross‐reactivity of the immune responses in these infections is an emerging concern, as pre‐existing DENV‐antibodies might potentially affect Covid‐19 through antibody‐dependent enhancement. In this review article, we aimed to raise the issue of Covid‐19 and dengue fever misdiagnosis, not only in a clinical setting but also with regards to cross‐reactivity between SARS‐CoV‐2 and DENV antibodies. We also have discussed the potential consequences of overlapping immunological cascades between dengue and Covid‐19 on disease severity and vaccine development.